NantHealth, Inc. (NH)
| Market Cap | 415.94M |
| Revenue (ttm) | 78.72M |
| Net Income (ttm) | -47.97M |
| Shares Out | 110.93M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $3.72 |
| Previous Close | $3.76 |
| Change ($) | -0.04 |
| Change (%) | -1.06% |
| Day's Open | 3.77 |
| Day's Range | 3.68 - 3.85 |
| Day's Volume | 823,288 |
| 52-Week Range | 1.11 - 5.99 |
Investors need to pay close attention to NantHealth (NH) stock based on the movements in the options market lately.
EL SEGUNDO, Calif. & SAN ANTONIO, Texas--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights...
CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insight...
NantHealth, Inc. (NH) Q3 2020 Results - Earnings Call Transcript
CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, presented virtually with NantOmics and ImmunityBio on S...
CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced a series of secure Application Programm...
CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced the national rollout of NaviNet AllPayer, a s...
NantHealth, Inc. (NH) Q2 2020 Results - Earnings Call Transcript
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -16.67% and -3.38%, respectively, for the quarter ended June 2020.
CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc.
CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the publication of a study in JCI Insig...
NantHealth (NH) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
NantHealth, Inc. (NH) Management on Q1 2020 Results - Earnings Call Transcript
NantHealth Inc (NH) delivered earnings and revenue surprises of 14.29% and -5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
These exciting stocks to buy for aggressive investors might be small, but they have massive growth potential when the pandemic clears up. The post 7 Top Stocks to Buy for Aggressive Investor...
Shares of NantHealth Inc. soared 56% in premarket trading on Tuesday after the company said it had developed an artificial intelligence software used to improve lung-cancer diagnoses.
NantHealth Scores Milestone FDA Approval While SaaS Business Grows
NantHealth, Inc. (NH) CEO Patrick Soon Shiong on Q3 2019 Results - Earnings Call Transcript
NantHealth, Inc. (NH) delivered earnings and revenue surprises of -75.00% and -4.46%, respectively, for the quarter ended September 2019.
NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
NantHealth's (NH) CEO Patrick Soon-Shiong on Q2 2019 Results - Earnings Call Transcript
NantHealth, Inc. (NH) delivered earnings and revenue surprises of 55.56% and 7.03%, respectively, for the quarter ended June 2019.
NantHealth, Inc. (NH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
NantHealth, Inc. (NH) CEO Patrick Soon-Shiong on Q1 2019 Results - Earnings Call Transcript
NantHealth's (NH) CEO Patrick Soon-Shiong on Q4 2018 Results - Earnings Call Transcript
About NH
NantHealth, together with its subsidiaries, operates as a healthcare technology company converging science and technology in the United States, the United Kingdom, Singapore, and Canada. It provides NantHealth solutions, including molecular profiling solutions, software-as-a-service platforms, and connected care medical device interoperability solutions to enable value-based care and evidence-based clinical practice. The company's products include GPS Cancer, a molecular profile that integrates whole genome/exome sequencing of tumor and normal ... [Read more...]
| Industry Health Information Services | IPO Date Jun 2, 2016 |
| CEO Patrick Soon-Shiong | Employees 398 |
| Stock Exchange NASDAQ | Ticker Symbol NH |
Financial Performance
In 2019, NantHealth's revenue was $95.96 million, an increase of 7.26% compared to the previous year's $89.46 million. Losses were -$62.76 million, -67.34% less than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for NantHealth stock is "Strong Buy." The 12-month stock price forecast is 3.75, which is an increase of 0.81% from the latest price.